Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revlimid To Launch With Risk Management Plan; Restrictions Could Be Lifted

Executive Summary

Celgene's Revlimid will launch under the risk management plan RevAssist to minimize fetal exposure, but the firm may lift the program if ongoing studies demonstrate there is no risk of teratogenicity

You may also be interested in...



Revlimid Cleared For Multiple Myeloma; Celgene Focuses On Thrombotic Risk

Celgene hopes to submit data to FDA showing that thromboembolic risks linked to Revlimid (lenalidomide) can be reduced with prophylactic anticoagulant use

Revlimid Cleared For Multiple Myeloma; Celgene Focuses On Thrombotic Risk

Celgene hopes to submit data to FDA showing that thromboembolic risks linked to Revlimid (lenalidomide) can be reduced with prophylactic anticoagulant use

FDA’s Rx/Dx Co-Development Approach Overlooks Incentives – Novartis Exec

FDA's concept paper on drug-diagnostic co-development does not account for "practical" issues facing firms, such as incentives, Novartis Oncology Diagnostic Development Director Mark Braganza said

Related Content

UsernamePublicRestriction

Register

PS046719

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel